Janux Therapeutics may be up for sale amid interest from major pharmaceutical firms. With shares quadrupling this year and a successful equity offering, Janux is making waves in the industry. The pharmaceutical industry has seen a surge in deal activities, with acquisitions totaling $27.8 billion since the year's start.
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday.
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.
The virtual event will take place on Monday, February 26th, 2024, at 4:30PM ETJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results.
Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1.